Donepezil

Drugs of Today

Volumn 34, Issue 4, 1998, Pages 321-326

  Whitehouse, Peter J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; FATIGUE; HUMAN; INSOMNIA; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VOMITING;

EID: 0031961565     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.4.472183     Document Type: Review

References (21)

1. Geldmacher, D.S., Whitehouse, P.J. Evaluation of dementia. A review. New Engl J Med 1996, 335: 330-5.
2. Whitehouse, P.J. Genesis of Alzheimer's disease. Neurology 1997, 48 (Suppl. 7): 1-6.
3. Whitehouse, P.J., Price, D.L., Struble, R.G., Clark, A.W., Coyle, J.T., DeLong, M.R. Alzheimer's disease senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215: 1237-9.
4. Whitehouse, P.J., Martino A.M., Antuono P.G. et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986, 371: 146-51.
5. Summers, W.K., Majovski, L.V., Marsh, G.M., Tachiki, K., Kling, A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. New Engl J Med 1986, 315: 1241-5.
6. Nochi, S., Asakawa, N., Sato, T. Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4[(5,6- dimethoxy-1-indanone)-2-yl]methyl piperidine hydrochloride (E2020). Biol Pharm Bull 1995, 18 (8): 1145-7.
7. Galli, A., Mori, F., Benini, L. et al. Acetylcholinesterase protection and the anti-diisopropyl fluorophosphate efficacy of E2020. Eur J Pharmacol Environ Toxicol Pharmacol 1994, 270: 189-93.
8. Yamanishi, Y., Ogura, H., Kosasa, T., Araki, S., Sawa, Y., Yamatusu, K. Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on cholinesterase, in comparison with other inhibitors. In: Basic, Clinical, and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, Vol. 2. Nagatsu, T., Fisher, A., Yoshida, M. (Eds.). Plenum Press: New York 1990, 409-13.
9. Kosasa, T., Yamanishi, Y., Ogura, H. et al. Effects of E2020 on the extracellular level of acetylcholine in the rat cerebral cortex measured by microcdialysis without addition of cholinesterase inhibitor. Eur J Pharmacol 1990, 183: Abst 1936.
10. Yamanishi, Y., Ogura, H., Kosasa, T. et al. Inhibitory action of E2020. a novel acetylcholinesterase inhibitor, on cholinesterase in aged rats. Eur J Pharmacol 1990, 183: Abst 1935.
11. Dawson, G.R., Iversen, S.D. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 1993, 57: 143-53.
12. van der Staay, F.J., Hinz, V.C., Schmidt, B.H. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats. J Pharmacol Exp Ther 1996, 278: 697-708.
13. Mihara, M., Ohnishi, A., Tomono, Y. et al. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993, 31: 223-9.
14. Sherman, K.A. Pharmacodynamics of oral E2020 and tacrine in humans: Novel approaches. In: Cholinergic Basis for Alzheimer Therapy. Becker, R., Giacobini, E. (Eds.). Birkhauser: Boston 1991, 321-8.
15. Rogers, S.L., Tiseo, P.J., Friedhoff, L.T. Pharmacokinetics of donepezil HCI (E2020) are unchanged in patients with impaired renal function. Clin Pharmacol Ther 1997, 61 (2): 217.
16. Tiseo, P.J., Rogers, S.L., Friedhoff, L.T. The pharmacokinetic profile of donepezil HCI (E2020) in patients with impaired liver function. Clin Pharmacol Ther 1997, 61 (2): 184.
17. Rogers, S.L., Farlow, M.R., Doody, R.S., Friedhoff, L.T., Mohs, R. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease (from study E2020-AO001-302). Neurology 1998, 50: 136-45.
18. Rogers, S.L., Friedhoff, L.T. and The Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trail. Dementia 1996, 7: 293-303.
19. Rogers, S.L., Doody, R.S., Mohs, R.C., Friedhoff, L.T. and The Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med, in press.
20. Rogers, S.L., Friedhoff, L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study (from study E2020-AO01-202). Eur Neuropsychopharmacol 1998, 8 (1): 67-75.
21. Whitehouse, P.J. Pharmacoeconomics. Alzheimer Dis Assoc Disord 1997, 11 (Suppl. 5): S22-31.